Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade

The aim of this study was to evaluate the effect of zoledronic acid (ZA) on bone mineral density (BMD) in patients with prostate cancer receiving combined androgen blockade (CAB) as a first-line androgen deprivation therapy. Patients receiving CAB for prostate cancer without bone metastasis were can...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishizawa, Satoshi, Inagaki, Takeshi, Iba, Akinori, Kikkawa, Kazuro, Kodama, Yoshiki, Matsumura, Nagahide, Kohjimoto, Yasuo, Hara, Isao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197198/
https://www.ncbi.nlm.nih.gov/pubmed/25332886
http://dx.doi.org/10.1186/2193-1801-3-586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197198/
https://www.ncbi.nlm.nih.gov/pubmed/25332886
http://dx.doi.org/10.1186/2193-1801-3-586

Ejemplares similares